Online inquiry

IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11370MR)

This product GTTS-WQ11370MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1&IGF2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000618.5; NM_000612.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3479; 3481
UniProt ID P05019; P01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11370MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5972MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ13024MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ7028MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ2398MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ1860MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ11065MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ7195MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ4716MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW